Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis

Michele Jara1 Drug Safety and Risk Management, Acorda Therapeutics, Inc, Ardsley, NY, USACorrespondence[email protected]

Matthew F Sidovar2 Clinical Development and Medical Affairs, Acorda Therapeutics, Inc, Ardsley, NY, USA

Herbert R Henney III2 Clinical Development and Medical Affairs, Acorda Therapeutics, Inc, Ardsley, NY, USA

Pages 1-7 | Published online: 16 Dec 2014

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

National Multiple Sclerosis Society.orgWho gets MS? (Epidemiology)New York2014 Available from: http://www.nationalmssociety.org/What-is-MS/Who-Gets-MSAccessed October 13, 2014
Google Scholar
WaxmanSGConduction in myelinated, unmyelinated, and demyelinated fibersArch Neurol19773410585589907529
PubMedGoogle Scholar
FrohmanEMMultiple sclerosisMed Clin North Am2003874867897 viii–ix12834152
PubMed Web of Science ®Google Scholar
Ampyra^® (dalfampridine) extended release tablets [prescribing information]Ardsley, NYAcorda Therapeutics, Inc2013
Google Scholar
HautSBienenEJMillerAClinical overview of the seizure risk of dalfampridineExpert Opin Drug Saf201211465165722703551
PubMed Web of Science ®Google Scholar
DeyoRACherkinDCCiolMAAdapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJ Clin Epidemiol19924566136191607900
PubMed Web of Science ®Google Scholar
Red BookMontvale, NJThomson Healthcare2009
Google Scholar
ZagariaMAECommon causes of drug-induced seizuresUS Pharm20103512023
Google Scholar
KelleyBJRodriguezMSeizures in patients with multiple sclerosis: epidemiology, pathophysiology and managementCNS Drugs2009231080581519739692
PubMed Web of Science ®Google Scholar
CalabresiPAAustinHRackeMKImpaired renal function in progressive multiple sclerosisNeurology200259111799180112473777
PubMed Web of Science ®Google Scholar
KuznikAMardekianJTarasenkoLEvaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001–2010BMC Nephrol20131413223802885
PubMed Web of Science ®Google Scholar
PrescottJDFactorSPillMLeviGWDescriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide databaseJ Manag Care Pharm2007131445217269836
PubMed Web of Science ®Google Scholar
MindenSHoaglinDJureidiniSDisease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis StudyMult Scler200814564065518566028
PubMed Web of Science ®Google Scholar
DworkinRHO’ConnorABAudetteJRecommendations for the pharmacological management of neuropathic pain: an overview and literature updateMayo Clin Proc2010853 supplS3S1420194146
PubMed Web of Science ®Google Scholar
PollmannWFenebergWCurrent management of pain associated with multiple sclerosisCNS Drugs200822429132418336059
PubMed Web of Science ®Google Scholar
O’ConnorABSchwidSRHermannDNMarkmanJDDworkinRHPain associated with multiple sclerosis: review proposed classificationPain200713719611117928147
PubMed Web of Science ®Google Scholar
McDonaghMPetersonKLeeNThakurtaSDrug class review: antiepileptic drugs for indications other than epilepsy. Update 2Portland, OROregon Health & Science University2008 Available from: http://www.ncbi.nlm.nih.gov/books/NBK10371/pdf/TOC.pdfAccessed October 13, 2014
Google Scholar
TrojanoMLiguoriMBosco ZimatoreGAge-related disability in multiple sclerosisAnn Neurol200251447548011921053
PubMed Web of Science ®Google Scholar
RunmarkerBAndersenOPrognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-upBrain1993116pt 11171348453453
PubMed Web of Science ®Google Scholar
TremlettHPatyDDevonshireVDisability progression in multiple sclerosis is slower than previously reportedNeurology200666217217716434648
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date